We are live on ! Find out more
PMCB icon

PharmaCyte Biotech
PMCB

23 hedge funds and large institutions have $632K invested in PharmaCyte Biotech in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 3

0.12% more ownership

Funds ownership: 8.28% → 8.4% (+0.12%)

4% less funds holding

Funds holding: 24 → 23 (-1)

11% less capital invested

Capital invested by funds: $710K → $632K (-$77.8K)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

Holders
23
Holders Change
-1
Holders Change %
-4.17%
% of All Funds
0.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
6
Reduced
3
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$11.9K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$10.3K
3
SSA
Schonfeld Strategic Advisors
New York
+$781
4
Bank of America
Bank of America
North Carolina
+$523
5
Renaissance Technologies
Renaissance Technologies
New York
+$335

Top Sellers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
-$13.8K
2
TRCT
Tower Research Capital (TRC)
New York
-$728
3
Vanguard Group
Vanguard Group
Pennsylvania
-$79
4
JP Morgan Chase
JP Morgan Chase
New York
-$20
5
BlackRock
BlackRock
New York
-$18
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$214K -$79 -71 -0%
Geode Capital Management
2
Geode Capital Management
Massachusetts
$139K -$13.8K -12,332 -9%
EPM
3
Equitec Proprietary Markets
Illinois
$90.2K – – –
Renaissance Technologies
4
Renaissance Technologies
New York
$54.3K +$335 +300 +0.6%
Susquehanna International Group
5
Susquehanna International Group
Pennsylvania
$30.4K +$10.3K +9,200 +50%
SSA
6
Schonfeld Strategic Advisors
New York
$28.6K +$781 +700 +3%
UBS Group
7
UBS Group
Switzerland
$24.6K +$11.9K +10,676 +90%
Dimensional Fund Advisors
8
Dimensional Fund Advisors
Texas
$22.3K – – –
Northern Trust
9
Northern Trust
Illinois
$20.9K – – –
National Bank of Canada
10
National Bank of Canada
Quebec, Canada
$3.56K – – –
TRCT
11
Tower Research Capital (TRC)
New York
$3.04K -$728 -653 -19%
Bank of America
12
Bank of America
North Carolina
$591 +$523 +469 +642%
Osaic Holdings
13
Osaic Holdings
Arizona
$331 +$329 +295 +2,950%
Raymond James Financial
14
Raymond James Financial
Florida
$48 +$49 +44 New
PSFG
15
Park Square Financial Group
Georgia
$40 – – –
S
16
Sachetta
Massachusetts
$16 – – –
BL
17
BFSG LLC
California
$6 – – –
NA
18
NewEdge Advisors
Louisiana
$2 – – –
KHC
19
Koesten Hirschmann & Crabtree
Kansas
$2 +$1 +1 New
IA
20
IFP Advisors
Florida
$1 – – –
Morgan Stanley
21
Morgan Stanley
New York
$1 – – –
JP Morgan Chase
22
JP Morgan Chase
New York
– -$20 -16 Closed
BlackRock
23
BlackRock
New York
– -$18 -14 Closed
Fidelity Investments
24
Fidelity Investments
Massachusetts
– -$8 -6 Closed

PMCB Hedge Fund Activity: Q2 2025 in Review

23 of the 7,603 institutional investors tracked by Wall St. Rank reported a position in PharmaCyte Biotech (PMCB) for Q2 2025, worth a combined $632K — down 11% from $710K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of PMCB and 2 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 6 added.

The largest buyer was UBS Group, adding an estimated $11.9K. The largest seller was Geode Capital Management, cutting an estimated $13.8K.

  • 23 institutional investors held PharmaCyte Biotech (PMCB) as of Q2 2025, down from 24 in Q1 2025.
  • Funds reported $632K of PharmaCyte Biotech stock for Q2 2025, down 11% quarter-over-quarter.
  • 2 funds opened new PharmaCyte Biotech positions in Q2 2025 and 3 closed out, a net change of -1 holder.
  • The largest PharmaCyte Biotech buyer in Q2 2025 was UBS Group, an estimated $11.9K added.
  • The largest PharmaCyte Biotech seller in Q2 2025 was Geode Capital Management, an estimated $13.8K sold.

Based on aggregated 13F filings for Q2 2025.